Crucell acquires ChromaGenics to strengthen its strategic position in protein production technology
"ChromaGenics' STARä technology involves higher-order gene regulation mechanisms and thereby has the potential to take biopharmaceutical production technology to a higher level of sophistication," says Ronald Brus, Chief Executive Officer of Crucell. "The potentially broad applicability of the STAR(TM) technology may lead to early additional licensing revenues for Crucell." Jaap Goudsmit, Chief Scientific Officer of Crucell, adds "We believe that ChromaGenics' STAR(TM) Technology will reduce the cost of industrial scale production of proteins and antibodies, to levels otherwise difficult to achieve."
Dr. Arie Otte, the discoverer of the STAR(TM) technology (Nature Biotechnology 2003 May, 21) will join Crucell part time as Director Epigenetics Technology, and five of his team will join Crucell fulltime.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous